Core B. Clinical Translational Core

核心 B. 临床转化核心

• 批准号: 10430107
• 负责人: Sally Ozonoff
• 金额: $ 32.45万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-21 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10430107
• 关键词: Address; Age; Assessment tool; Behavioral; Biological; California; Characteristics; Childhood; Chromosomes; Clinical; Clinical Trials; Collection; DiGeorge Syndrome; Diagnostic; Dimensions; Disease; Doctor of Philosophy; Down Syndrome; Economics; Ensure; Ethnic Origin; Evaluation; Failure; Fragile X Syndrome; Freezing; Funding; Genetic; Genomic medicine; Genomics; Health; Health Technology; Heterogeneity; Human; Incentives; Individual; Infrastructure; Institutes; Intellectual and Developmental Disabilities Research Centers; Investigation; Lead; Libraries; Link; Measures; Methodology; Molecular Analysis; Monitor; Mood Disorders; National Institute of Child Health and Human Development; Participant; Patient Recruitments; Phenotype; Population; Problem Solving; Process; Productivity; Race; Registries; Research; Research Personnel; Resources; Science; Scientist; Services; Site; Standardization; Symptoms; Technology; Testing; Training; Translations; Universities; Variant; Venous blood sampling; autism spectrum disorder; biobehavior; community engagement; comorbidity; comparison group; cost; cost effective treatment; cost effectiveness; design; experience; improved; inclusion criteria; innovation; interest; neurobehavioral; neuropathology; patient engagement; programs; psychologic; recruit; standardize measure; telehealth; tool

PROJECT SUMMARY – CLINICAL TRANSLATIONAL CORE The present application seeks funding to continue the MIND Institute Intellectual and Developmental Disabilities Research Center (IDDRC) at the University of California, Davis. The IDDRC was launched in 2013 and is the newest of the 14 IDDRCs in the network. The Clinical Translational Core (CTC) is designed to establish and maintain an operational framework that is optimal for recruitment, diagnostic assessment, neurobehavioral characterization, and mapping of phenotypes to underlying biological mechanisms for a diverse range of clinical populations. The CTC will address five specific aims. Aim 1 is to enhance recruitment of a diverse range of participants. This aim will be met through systematic community engagement and a growing participant registry that includes multiple ethnicities, races, and economic backgrounds with both atypical and typical populations across a wide age span. Aim 2 is to provide behavioral and diagnostic characterization of human participants. This aim will be met by providing access to experienced clinicians who can conduct specialized evaluations, advise studies in best practices, provide training in administration of standardized measures, establish initial reliability, and monitor administration fidelity, as well as by providing access to specialized testing space and connect investigators with clinical trials expertise. Aim 3 is to provide access to state-of-the-art “deep phenotyping” tools and expertise in genomics. This aim will be met by offering tools and training to enhance phenotypic characterization of participants, making available recent innovations in deep phenotyping and genomics to IDDRC investigators. Aim 4 is to support the integration of technology into research, especially telehealth methodologies that can lead to scalable, accessible, and cost-effective treatments for IDD conditions. This aim will be met by providing on-site high-level research IT support and access to the full array of technologies and expertise at UC Davis Health. Aim 5 is to facilitate collection and analysis of biospecimens from human participants and promote sharing across IDDRC projects. This aim will be met by providing phlebotomy services and access and incentives to use a core-managed freezer library for biospecimen storage as well as by links to the MIND IDDRC Biological and Molecular Analysis Core and the MIND Institute Genomic Medicine Program. The proposed CTC has been significantly expanded relative to the previous funding period, with the most significant change being the integration of the deep phenotyping and measure dissemination functions of the previous Neurobehavioral Analysis Core, which has led us to rename this expanded core, the CTCx. The Director of the CTC is Sally Ozonoff, PhD.

项目摘要 – 临床转化核心 本申请寻求资金以继续 MIND 研究所智力与发展 加州大学戴维斯分校残疾人研究中心 (IDDRC)。 IDDRC 于 2013 年启动 是网络中 14 个 IDDRC 中最新的一个。临床转化核心 (CTC) 旨在建立 并维持一个最适合招募、诊断评估、神经行为学的运营框架 表型的表征和映射到各种临床的潜在生物学机制 人口。反恐委员会将实现五个具体目标。目标 1 是加强招聘多元化人才 参与者。这一目标将通过系统的社区参与和不断增长的参与者登记来实现 其中包括具有非典型和典型人群的多个民族、种族和经济背景 跨越了很宽的年龄跨度。目标 2 是提供人类参与者的行为和诊断特征。 这一目标将通过提供能够进行专门评估的经验丰富的临床医生来实现， 为最佳实践研究提供建议，提供标准化措施管理培训，建立初步的 可靠性，并监控管理保真度，以及通过提供专门的测试空间和 将研究人员与临床试验专业知识联系起来。目标 3 是提供最先进的“深度学习” “表型分析”工具和基因组学专业知识。这一目标将通过提供工具和培训来实现 参与者的表型特征，提供深度表型分析的最新创新和 IDDRC 研究人员的基因组学。目标 4 是支持技术融入研究，特别是 远程医疗方法可以为 IDD 疾病提供可扩展、可访问且具有成本效益的治疗方法。 这一目标将通过提供现场高水平研究 IT 支持和访问全套信息来实现。 加州大学戴维斯分校健康中心的技术和专业知识。目标 5 是促进生物样本的收集和分析 来自人类参与者并促进 IDDRC 项目之间的共享。这一目标将通过提供 放血服务以及使用核心管理的冷冻库存储生物样本的准入和激励措施 以及 MIND IDDRC 生物和分子分析核心和 MIND 研究所基因组的链接 医学计划。拟议的 CTC 相对于之前的资助期已显着扩大， 最显着的变化是深度表型分析和测量传播的整合 之前的神经行为分析核心的功能，这导致我们将这个扩展核心重新命名为 CTCx。 CTC 主任是 Sally Ozonoff 博士。